Viva Biotech IPO: Just About Supporting the Low-End IPO Price Range
Viva Biotech Holdings (1873 HK) is a leading global contract research organisation (CRO). It has launched its IPO to raise net proceeds of HK$1,232...
670 Views
India Generic Drugs: Antitrust Suit Could Cost Billions
This Insight builds on our previous Insight, India Generic Drugs: US Antitrust Inquiry Widens by discussing estimated potential liabilities and...
780 Views
WuXi AppTec IPO Valuation: Not Much Money Left on the Table
WuXi AppTec Co. Ltd. (WUXI HK) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....
592 Views
WuXi AppTech IPO Update: Figuring Out the Right AH Premium
WuXi AppTec Co. Ltd. (WUXI HK) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....
708 Views
Wuxi Apptec 药明康德 IPO: Welcome to the A/H Universe
WuXi Apptec is set to be the newest A/H pair with its upcoming HK listing that is set to raise USD 1 billion. The A-share (603289 CH) recorded 15...
830 Views